Founder of Somatix Therapy Corp. and Sarissa Capital Management LP, Richard Charles Mulligan presently occupies the position of Executive Vice Chairman & Head-SanaX at Sana Biotechnology, Inc. Dr. Mulligan is also on the board of Biogen, Inc., Biogen GmbH, Bausch Health Cos., Inc. and Kadmon Pharmaceuticals LLC and Member of US Food & Drug Administration and Professor at Harvard Medical School.

In his past career Dr. Mulligan occupied the position of Senior Managing Director & Founding Partner at Sarissa Capital Management LP, Chief Scientific Officer at Somatix Therapy Corp., Portfolio Manager at Icahn Capital LP, Professor-Molecular Biology at Massachusetts Institute of Technology and Member of Whitehead Institute for Biomedical Research.

Richard Charles Mulligan received an undergraduate degree from Massachusetts Institute of Technology and a doctorate from Stanford University School of Medicine.